Waystone Advisors’s Boston Scientific BSX Stock Holding History

Waystone Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,364	Closed	-$225K	–	103
2025 Q4	$225K	Buy	+2,364	New	+$232K	0.19%	95

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Waystone Advisors's BSX Position: Q1 2026 in Review

Waystone Advisors sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,364 shares — an estimated $225K sold.

Waystone Advisors first reported a position in BSX in Q4 2025 and held it in 1 quarter. The position peaked at $225K in Q4 2025. 1,683 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Waystone Advisors reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Waystone Advisors sold 2,364 Boston Scientific shares in Q1 2026, an estimated $225K.
Waystone Advisors first reported a position in Boston Scientific in Q4 2025 and held it in 1 quarter.
Waystone Advisors's Boston Scientific position peaked at $225K in Q4 2025.
1,683 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Waystone Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.